RecallRadar

FDA Drug recall D-1546-2022

ClomiPRAMINE Hydrochloride Capsules, USP 25mg, 100-count bottles, Rx only, LEADING PHARMA, Manufactured by: Leading Pharma, LLC, Fairfield,…

On 2022-10-05 the FDA classified a Class III recall of ClomiPRAMINE Hydrochloride Capsules, USP 25mg, 100-count bottles, Rx only, LEADING PHARMA, Manufactured by: Leading Pharma, LLC, Fairfield,… by Leading Pharma, citing superpotent Drug: Assay value found to be 110.6% in Chlomipramine Hydrocholoride capsules.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-1546-2022
ClassificationClass III
Statusterminated
Initiated2022-08-23
Published2022-10-05
Last updated2026-09-13 11:52 UTC
CompanyLeading Pharma
DistributionUS

Product

ClomiPRAMINE Hydrochloride Capsules, USP 25mg, 100-count bottles, Rx only, LEADING PHARMA, Manufactured by: Leading Pharma, LLC, Fairfield, NJ 07004, NDC 69315-167-01

Reason

Superpotent Drug: Assay value found to be 110.6% in Chlomipramine Hydrocholoride capsules

Identifiers

ndc69315-167-03
ndc69315-167-01
ndc69315-167-09
ndc69315-166-03
ndc69315-166-01
ndc69315-166-09
ndc69315-165-03
ndc69315-165-01
code_infoLot#: B14221, Exp. Date 02/2023

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1546-2022%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.